Evidence map›Paper›PMID 40213424›Full record

ArticleFrontiers in public health2025

Immunogenicity and predictive factors of hepatitis B vaccination with Fendrix

Cristina Hernán-García, Daniel Leonardo Sánchez-Carmona, Lucía Czestochowa Mateo-Otero, Virginia Fernández-Espinilla, Paula Andrea Rodriguez-Ducuara, José Javier Castrodeza-Sanz, Camino Prada-García

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cristina Hernán-García *Preventive Medicine and Public Health Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Daniel Leonardo Sánchez-Carmona *Preventive Medicine and Public Health Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Lucía Czestochowa Mateo-OteroDepartment of Oncology, Hospital Universitario Río Hortega, Valladolid, Spain.
Virginia Fernández-EspinillaPreventive Medicine and Public Health Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Paula Andrea Rodriguez-DucuaraPreventive Medicine and Public Health Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
José Javier Castrodeza-SanzPreventive Medicine and Public Health Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Camino Prada-GarcíaDepartment of Preventive Medicine and Public Health, University of Valladolid, Valladolid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection and chronic kidney disease (CKD) pose major global health challenges. CKD patients face a heightened risk of HBV infection, worsening their prognosis. This study evaluated the immune response to hepatitis B vaccination in CKD patients, the persistence of antibodies, and factors influencing vaccine efficacy. A retrospective study was conducted on 173 CKD patients (2014-2019) receiving routine vaccination at the Hospital Clínico Universitario de Valladolid, Spain. (ZIP Code:47003) Patients were immunized with Fendrix

Indexed as

Hepatitis BHepatitis B VaccinesRenal Insufficiency, ChronicAdultAgedFemaleHepatitis B AntibodiesHumansMaleMiddle AgedRetrospective StudiesSpainVaccinationFendrixHepatitis B AntibodiesHepatitis B Vaccineschronic kidney diseasedialysishepatitis B vaccine (HBV)observationalvaccination

Identifiers

PMID40213424
PMCPMC11983650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.